<DOC>
	<DOCNO>NCT02483455</DOCNO>
	<brief_summary>This single-center , randomize , double blind , vehicle-controlled phase 2 study subject 8 year age old Common Warts ( Verruca vulgaris ) desire treatment .</brief_summary>
	<brief_title>ALC-919 For The Treatment Of Common Warts</brief_title>
	<detailed_description>This single-center , randomize , double blind , vehicle-controlled phase-2 study subject 8 year age old Common Warts ( Verruca vulgaris ) desire treatment . A total four visit plan include one baseline three follow-up . Screening do Visit 1 ( Baseline ) safety efficacy measurement make subsequent visit ( Visits 2-4 ) . The primary objective evaluate efficacy twice daily-applied ALC-919 vs. vehicle male female subject 8 year age old Common Warts ( Verruca vulgaris ) . The primary outcome measure complete resolution lesion 12 week visit . Secondary outcome measure include change lesion count 12 week visit , improvement Global Aesthetic Improvement Scale score 12 week visit safety tolerability profile treatment arm compare vehicle arm study visit . The safety assess use clinical cutaneous safety exam report scaling , dryness erythema scale 0-3 ( 0= absent , 1=mild . 2=moderate , 3=severe ) . Tolerability assess subject answer treatment tolerability question visit treatment period . The tolerability question assess use 0-3 scale itching , burning , sting .</detailed_description>
	<mesh_term>Warts</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Males female age 8 year old ; Individuals least 1 , exceed 10 Common Wart ( ) ( Verruca vulgaris ) treat ; Individuals whose treatment area locate anywhere body except follow prohibited area include : eye area ( include eyelid ) , lip , mouth cavity , nasal cavity , inner ear , palm hand ( include periungual area ) , sole foot ( include periungual area ) , anogenital area ; Individuals generally good health determine Principal Investigator ; Willingness ability read , understand , sign IRBapproved inform consent form English nature study fully explain question answer ; Individuals willing start new product OTC prescription treatment discontinue treatment Principal Investigator feel may interfere evaluation test product ; Individuals willing avoid use cosmetic product , cream , salve , ointment treatment area ( ) ; Individuals willing able thoroughly follow product use instruction , attend schedule visit successfully complete study ; Individuals willing able begin office base treatment duration study ; Individuals determine free systemic dermatologic disorder , , opinion Principal Investigator , interfere study result ; Female subject determine childbearing potential must indicate best knowledge pregnant and/or lactate intend become pregnant participation study ; Female subject reproductive potential must agree practice medically acceptable form birth control study ; A female subject postmenopausal ( amenorrhea 12 month prior Baseline Visit ) consider reproductive potential . Have wart outside treatment area , eye area ( include eyelid ) , lip , mouth cavity , nasal cavity , inner ear , palm hand ( include periungual area ) , sole foot ( include periungual area ) , anogenital area ) area would interfere study procedure analyse ; Have participate investigational trial within 30 day prior enrollment ; Have receive cryotherapy treatment area within 30 day prior enrollment ; Have require require systemic intake immunosuppressive immunomodulatory medication ( include oral parenteral corticosteroid ) within 30 day prior enrollment course study . Routine use inhale intranasal corticosteroid study allow Have uncontrolled current infection ; Female subject pregnant , lactate plan become pregnant , breastfeed ; Have chronic acute medical condition , opinion investigator , may interfere study result place subject undue risk ( immunodeficiency relevant genetic syndrome ) ; Have active malignancy undergo treatment malignancy nonmelanoma skin cancer ; Individuals mentally incompetent , unable willing give write informed consent meet study requirement ; Subjects view Principal Investigator able complete study . Subjects know history irritation allergy cause povidoneiodine Have excessive number Common Warts ( Verruca vulgaris ) , define great 10</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>